Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Abrysvo (bivalent RSV vaccine by Quarter
Abrysvo (bivalent RSV vaccine — maternal & older adults) — U.S. reported YoY (%) (%)
Pfizer Abrysvo (bivalent RSV vaccine: -46.0% in Q2 2026.
Latest, Q2 2026
-46.0%
Period ended Jun 28, 2026
Change on a year earlier
–
History
7 quarters
Since Q3 2024
Sources
7
Documents cited below
Where the Q2 2026 figure comes from
“|| Abrysvo | 208 | 143 | 46% | 43% | 55 | 101 | (46%) | 153 | 42 | * | *”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Abrysvo (bivalent RSV vaccine — maternal & older adults) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | -46.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 33.0% | +85.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 61.0% | +141.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 28, 2025 | -34.0% | -19.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗ |
| Q1 2025 | Mar 30, 2025 | -52.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | -80.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| Q3 2024 | Sep 29, 2024 | -15.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗ |
Cite this data
StockData. (2026). Pfizer Abrysvo (bivalent RSV vaccine (%), quarterly Q3 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/abrysvo-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.